Alk-Abello AS (CHIX:ALKBC) Debt-to-Equity : 0.10 (As of Sep. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Alk-Abello AS Debt-to-Equity?

Alk-Abello AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr66 Mil. Alk-Abello AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was kr444 Mil. Alk-Abello AS's Total Stockholders Equity for the quarter that ended in Sep. 2024 was kr5,086 Mil. Alk-Abello AS's debt to equity for the quarter that ended in Sep. 2024 was 0.10.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Alk-Abello AS's Debt-to-Equity or its related term are showing as below:

CHIX:ALKBc' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.1 Med: 0.23 Max: 0.31
Current: 0.1

During the past 13 years, the highest Debt-to-Equity Ratio of Alk-Abello AS was 0.31. The lowest was 0.10. And the median was 0.23.

CHIX:ALKBc's Debt-to-Equity is ranked better than
58.06% of 1023 companies
in the Biotechnology industry
Industry Median: 0.14 vs CHIX:ALKBc: 0.10

Alk-Abello AS Debt-to-Equity Historical Data

The historical data trend for Alk-Abello AS's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello AS Debt-to-Equity Chart

Alk-Abello AS Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.31

0.30

0.20

0.18

0.17

Alk-Abello AS Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Debt-to-Equity	Get a 7-Day Free Trial															0.17	0.17	0.11	0.10	0.10

Competitive Comparison of Alk-Abello AS's Debt-to-Equity

For the Biotechnology subindustry, Alk-Abello AS's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alk-Abello AS's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello AS's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Alk-Abello AS's Debt-to-Equity falls into.

Alk-Abello AS Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Alk-Abello AS's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(326	+	439)	/	4447
	=	0.17

Alk-Abello AS's Debt to Equity Ratio for the quarter that ended in Sep. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(66	+	444)	/	5086
	=	0.10

Alk-Abello AS (CHIX:ALKBc) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Alk-Abello AS Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Alk-Abello AS's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Alk-Abello AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello AS (CHIX:ALKBc) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AKBLF:USA 0OIR:UK ALK B:Denmark 4AJ0:Germany

Address

Boge Alle 6-8, Horsholm, DNK, DK-2970

Website

https://www.alk.net

Alk-Abello AS is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication. The company operates in Europe, North America and International Markets. It derives maximum revenue from Europe.

Alk-Abello AS Headlines

No Headlines